Outcomes of primary membranous nephropathy refractory to immunosuppressants.
作者信息
Nayak Saurabh, Chauhan Prabhat, Jha Vivekanand, Ramachandran Raja, Bose Bhadran
机构信息
Department of Nephrology, All India Institute of Medical Sciences, Bathinda, India.
Department of Nephrology, Indian Naval Hospital Ship Asvini, Mumbai, India.
出版信息
Clin Kidney J. 2024 Apr 15;17(5):sfae113. doi: 10.1093/ckj/sfae113. eCollection 2024 May.
Abstract
摘要
相似文献
1
Outcomes of primary membranous nephropathy refractory to immunosuppressants.免疫抑制剂难治性原发性膜性肾病的治疗结果
Clin Kidney J. 2024 Apr 15;17(5):sfae113. doi: 10.1093/ckj/sfae113. eCollection 2024 May.
2
Case report: Successful treatment of refractory membranous nephropathy with telitacicept.病例报告：替利泰塞普特成功治疗难治性膜性肾病。
Front Immunol. 2023 Oct 17;14:1268929. doi: 10.3389/fimmu.2023.1268929. eCollection 2023.
3
An 8-month-old boy with infantile nephrotic syndrome caused by semaphorin 3B-associated membranous nephropathy.一名 8 月龄男婴，因 semaphorin 3B 相关膜性肾病引起的婴儿期肾病综合征。
CEN Case Rep. 2023 Aug;12(3):281-286. doi: 10.1007/s13730-022-00763-6. Epub 2022 Dec 12.
4
An Unusual Progression of Membranous Nephropathy.膜性肾病的一种不寻常进展。
Cureus. 2022 Oct 25;14(10):e30651. doi: 10.7759/cureus.30651. eCollection 2022 Oct.
5
Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population.利妥昔单抗治疗巴基斯坦人群难治性特发性膜性肾病
J Ayub Med Coll Abbottabad. 2019 Apr-Jun;31(2):265-268.
6
Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience.利妥昔单抗治疗特发性膜性肾病疗效的初步研究：单中心经验。
Front Endocrinol (Lausanne). 2023 Feb 15;14:1044782. doi: 10.3389/fendo.2023.1044782. eCollection 2023.
7
Effects of hydroxychloroquine on proteinuria in membranous nephropathy.羟氯喹对膜性肾病蛋白尿的影响。
J Nephrol. 2022 May;35(4):1145-1157. doi: 10.1007/s40620-021-01182-z. Epub 2021 Nov 30.
8
IgG4-related kidney disease (IgG4-RKD) with membranous nephropathy as its initial manifestation: report of one case and literature review.以膜性肾病为首发表现的 IgG4 相关肾脏疾病：1 例报告并文献复习。
BMC Nephrol. 2019 Jul 16;20(1):263. doi: 10.1186/s12882-019-1419-6.
9
Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with obinutuzumab.用奥滨尤妥珠单抗成功治疗与免疫球蛋白G4相关疾病相关的膜性肾病。
Clin Kidney J. 2021 Dec 8;15(3):564-566. doi: 10.1093/ckj/sfab250. eCollection 2022 Mar.
10
Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy.原发性膜性肾病及其对利妥昔单抗耐药的治疗进展。
Front Immunol. 2022 May 4;13:859419. doi: 10.3389/fimmu.2022.859419. eCollection 2022.
引用本文的文献
1
Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights.泰它西普与他克莫司联合治疗难治性原发性膜性肾病：病例分析
Am J Case Rep. 2025 Apr 23;26:e946727. doi: 10.12659/AJCR.946727.
本文引用的文献
1
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.KDIGO 2021肾小球疾病管理临床实践指南。
Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.
2
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.利妥昔单抗治疗重度膜性肾病：一项为期6个月的试验及延长随访
J Am Soc Nephrol. 2017 Jan;28(1):348-358. doi: 10.1681/ASN.2016040449. Epub 2016 Jun 27.
3
A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.一项关于类固醇和环磷酰胺治疗特发性膜性肾病所致成人肾病综合征的随机对照试验。
J Am Soc Nephrol. 2007 Jun;18(6):1899-904. doi: 10.1681/ASN.2007020166. Epub 2007 May 9.
4
Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial.他克莫司单药治疗膜性肾病：一项随机对照试验。
Kidney Int. 2007 May;71(9):924-30. doi: 10.1038/sj.ki.5002215. Epub 2007 Mar 21.
5
Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis.预测特发性膜性肾小球肾炎中的慢性肾功能不全
Kidney Int. 1992 Oct;42(4):960-6. doi: 10.1038/ki.1992.374.
Zotero 插件